Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Leal James

2. Date of Event Requiring Statement (MM/DD/YYYY) 6/2/2021

3. Issuer Name and Ticker or Trading Symbol

TANDEM DIABETES CARE INC [TNDM]

(Last) (First) (Middle)

C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
SVP, Operations /

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3596	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option ⁽¹⁾	⁽²⁾	⁽³⁾	Common Stock	835.0	$251.34	D
Stock Option ⁽¹⁾	⁽²⁾	⁽³⁾	Common Stock	59.0	$251.34	D
Stock Option ⁽⁴⁾	⁽⁵⁾	⁽³⁾	Common Stock	1301.0	$150.0	D
Stock Option ⁽⁴⁾	⁽⁵⁾	⁽³⁾	Common Stock	8798.0	$150.0	D
Stock Option ⁽⁴⁾	⁽⁶⁾	⁽³⁾	Common Stock	800.0	$119.2	D
Stock Option ⁽⁴⁾	⁽⁶⁾	⁽³⁾	Common Stock	1459.0	$119.2	D
Stock Option ⁽⁴⁾	⁽⁷⁾	⁽³⁾	Common Stock	3390.0	$69.5	D
Stock Option ⁽⁴⁾	⁽⁸⁾	⁽³⁾	Common Stock	468.0	$9.0	D
Stock Option ⁽⁴⁾	⁽⁹⁾	⁽³⁾	Common Stock	40000.0	$51.5	D
Stock Option ⁽⁴⁾	⁽¹⁰⁾	⁽³⁾	Common Stock	11436.0	$82.34	D
Restricted Stock Unit ⁽⁴⁾	⁽¹¹⁾	⁽¹¹⁾	Common Stock	3716.0	$0.0	D
Stock Option ⁽⁴⁾	⁽¹²⁾	⁽³⁾	Common Stock	4095.0	$81.63	D
Restricted Stock Unit ⁽⁴⁾	⁽¹³⁾	⁽¹³⁾	Common Stock	2681.0	$0.0	D

Explanation of Responses:
(1)	Granted pursuant to the Tandem Diabetes Care, Inc. 2006 Stock Incentive Plan.
(2)	The date of grant of the option was 01/30/2012. All shares subject to the option have vested.
(3)	The expiration date for these options is 10 years from the date of grant.
(4)	Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").
(5)	The date of grant of the option was 11/13/2013. All shares subject to the option have vested.
(6)	The date of grant of the option was 05/21/2015. All shares subject to the option have vested.
(7)	The date of grant of the option was 02/16/2016. All shares subject to the option have vested.
(8)	The date of grant of the option was 05/17/2017. All shares subject to the option have vested.
(9)	The date of grant of the option was 02/15/2019. 25% of the shares subject to the option vested on 02/15/2020 and the remainder vests in 36 equal monthly installments thereafter.
(10)	The date of grant of the option was 05/27/2020. 25% of the shares subject to the option vested on 05/27/2021 and the remainder vests in 36 equal monthly installments thereafter.
(11)	The date of Restricted Stock Unit ("RSU") grant was 05/27/2020. RSU vested as to twenty-five percent (25%) of the total number of shares subject to the RSU on the one year anniversary of the grant date, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.
(12)	The date of grant of the option was 05/18/2021. 25% of the shares subject to the option will vest on 05/18/2022 and the remainder vests in 36 equal monthly installments thereafter.
(13)	The date of Restricted Stock Unit ("RSU") grant was 05/18/2021. RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 05/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Leal James C/O TANDEM DIABETES CARE, INC. 11075 ROSELLE STREET SAN DIEGO, CA 92121			SVP, Operations